An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10478678" target="_blank" >RIV/00064165:_____/24:10478678 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10478678
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=aH4G-C4cOK" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=aH4G-C4cOK</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14712598.2024.2312243" target="_blank" >10.1080/14712598.2024.2312243</a>
Alternative languages
Result language
angličtina
Original language name
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas
Original language description
Introduction: Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R) after the treatment. The prognosis of this patient cohort remains poor. Novel strategies mainly based on immunotherapy and targeted agents are currently being studied. Glofitamab is novel T-cell-engaging bispecific antibody possessing a 2:1 structure with bivalent CD20 binding. Its safety and efficacy in R/R B-cell non-Hodgkin lymphoma including DLBCL were evaluated in phase I-II NP30179 trial. Areas covered: The article summarizes the milestones and latest reports on glofitamab development in the field of B-cell lymphoma treatment. Expert opinion: Recently, phase II part of the NP30179 study and several other reports were published proving glofitamab potential in R/R DLBCL patients. Based on the published data, glofitamab was approved by regulatory authorities worldwide for the monotherapy of R/R DLBCL in conventional time-limited manner. It is readily accessible in case of rapidly progressing disease, and it compares well with other novel treatment options. Its side effects are similar to those of other T-cell-engaging agents and can be mitigated by pretreatment with obinutuzumab or step-up dosing. Its safety profile with manageable toxicities heads the clinical development toward combination strategies and its use in earlier therapeutic phases.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NU21-03-00411" target="_blank" >NU21-03-00411: Early identification of prognostic factors connected with worse outcome of Non-Hodgkin’s Lymphoma</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert Opinion on Biological Therapy
ISSN
1471-2598
e-ISSN
1744-7682
Volume of the periodical
24
Issue of the periodical within the volume
1-2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
7-13
UT code for WoS article
001155438400001
EID of the result in the Scopus database
2-s2.0-85184264803